| [1］ Riska A, Leminen A. Determinants of incidence of primary fallopian tube carcinoma (PFTC)[J]. Methods Mol Biol，2009，472:387-396. [2］ Alvarado-Cabrero I, Young RH, Vamvakas EC, et al. Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors[J]. Gynecol Oncol，1999，72(3):367-379. [3］ Kietpeerakool C, Suprasert P, Srisomboon J, et al. Primary carcinoma of the fallopian tube: A clinicopathologic analysis of 27 patients[J]. J Med Assoc Thai，2005，88(10):1338-1343. [4］ Ajithkumar TV, Minimole AL, John MM, et al. Primary fallopian tube carcinoma[J]. Obstet Gynecol Surv，2005，60(4):247-252. [5］ Rosenblatt KA, Weiss NS, Schwartz SM. Incidence of malignant fallopian tube tumors[J]. Gynecol Oncol，1989 ，35(2):236-239. [6］ Baumann KH, Wagner U, du Bois A. The changing landscape of therapeutic strategies for recurrent ovarian cancer[J]. Future Oncol，2012 ，8(9):1135-1147. [7］ Risum S, Hgdall C, Markova E, et al. Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery[J]. Int J Gynecol Cancer，2009 ，19(4):600-604. [8］ Safra T, Berman T, Yachnin A, et al. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience[J]. Int J Gynecol Cancer，2013 ，23(3):475-480. |
